60 Degrees updates investor presentation on tafenoquine sNDA path
60 Degrees Pharmaceuticals updated its investor presentation, outlining a tafenoquine strategy to pursue an sNDA for babesiosis and highlighting Q2 product revenue and July financing details.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.